BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GeneOhm Sciences, Inc. Announces Evanston Northwestern Healthcare System MRSA Testing Program; World Class Healthcare Institution Initiates Screening Program


10/19/2005 5:09:12 PM

SAN DIEGO--(BUSINESS WIRE)--Sept. 1, 2005--GeneOhm Sciences, an emerging leader in molecular diagnostics, is pleased to announce that the Evanston Northwestern Healthcare (ENH) system has selected GeneOhm's IDI-MRSA(TM) assay for use in a comprehensive, hospital-wide admission screening program to detect colonization by Methicillin-resistant Staphylococcus aureus (MRSA). This first-of-its-kind program in the U.S. will assess all admissions to the hospital for determination of colonization with MRSA. The IDI-MRSA(TM) assay is currently in use at numerous leading institutions in the US, Canada, UK, and Europe. Evanston Northwestern Healthcare is a leader in advancing medicine to improve patient care. The group has been screening high-risk patients for the past two years and has selected GeneOhm's rapid molecular-based method for expansion of the testing of admissions. The three-hospital wide program will identify those patients who are colonized with MRSA almost immediately on admission, allowing physicians and staff to provide the best and most immediate treatment opportunities for the patient.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES